News

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

  • bioAffinity Technologies shares 3 new case studies in which CyPath Lung detected Stage 1A lung cancer or prevented unnecessary invasive procedures.
    09/26/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

bioAffinity Technologies, Inc. (BIAFW) can sell. Click on Rating Page for detail.

The price of bioAffinity Technologies, Inc. (BIAFW) is 0.488 and it was updated on 2025-10-13 09:00:26.

Currently bioAffinity Technologies, Inc. (BIAFW) is in undervalued.

SEC Filings
SEC Filings
Unlock
BIAFW Ratings Summary
BIAFW Quant Ranking